NCT00403325|CompletedPhase 1
Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy
Phase I Study of Intravitreally Administered Ranibizumab in Subjects With Unresolving CSC and Subfoveal Fluid.
Loading search results
Phase I Study of Intravitreally Administered Ranibizumab in Subjects With Unresolving CSC and Subfoveal Fluid.
Sponsor study identifier
interventional
9
1 country
1
Study Start
August 2006
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
Not reported
Date not reportedThe purpose of this study is to examine the effects of Lucentis for active Central Serous Chorioretinopathy.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 2006
Date type not reportedThis date has not been verified as actual or estimated.
November 22, 2006
Actual (reported)November 23, 2006
Actual (reported)To determine the safety and tolerability of 0.5 mg dose of Ranibizumab in the treatment of chronic central serous retinopathy (CSC)
Mean change in VA compared to baseline at month 6 and month 12
Proportion of patients with 20/20 vision at month 6 and 12 as compared to baseline
Proportion of patients losing ≤ 15 letters as measured by ETDRS visual refraction at 4 meters compared to baseline at month 6 and 12
Proportion of patients gaining ≥ 15 letters as measured by ETDRS visual refraction at 4 meters compared to baseline at month 6 and 12
Change in subretinal fluid (as measured by optical coherence tomography) from baseline at month 3, 6, 9 and 12
Vitreous Retina Macula Consultants of New York, P.C.
New York, New York, 10022, United States
Richard F. Spaide, M.D.
Vitreous Retina Macula Consultants of New York, P.C.
9 participants (actual enrollment reported by the registry).
First Submitted
November 22, 2006
First Posted
November 23, 2006
Study Start
August 2006
Date type not reportedThis date has not been verified as actual or estimated.
Effect of Ranibizumab on Malignant Conjunctival Neoplasia
Contact the study team to confirm eligibility.
Last Updated
November 3, 2008
Record last verified: 2008-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: